Mayo Clinic Affiliated PEMF Technology Research

A closer look at the technology behind NeuroRester

Reframed from: Stewart GM, Wheatley-Guy CM, Johnson BD, Shen WK, Kim CH (2020). "Impact of pulsed electromagnetic field therapy on vascular function and blood pressure in hypertensive individuals." Journal of Clinical Hypertension. DOI: 10.1111/jch.13877

Vascular function research from Mayo Clinic's Department of Cardiovascular Disease

Cardiovascular researchers at the Mayo Clinic (Rochester, MN and Phoenix, AZ) conducted a second double-blind, randomized study examining the same underlying PEMF protocol, this time with a specific focus on vascular function — how well blood vessels dilate in response to increased blood flow, a widely used marker of vascular health.

Study design

30 participants were randomly assigned to an active PEMF group or a control group; 26 completed the 12-week protocol (15 active, 11 control). Vascular function was measured using flow-mediated dilation (FMD), a standard ultrasound-based technique, alongside standard circulatory markers. Adherence was high in both groups (94–96%).

What researchers observed

P-values shown for the PEMF and control columns reflect within-group pre-to-post comparisons unless otherwise indicated.

Why it's worth noting

Vascular reactivity is considered an important indicator of overall circulatory health, and the researchers noted that the improvement observed in the PEMF group compares favorably to the kind of differences seen between generally healthy individuals and those with elevated cardiovascular risk factors in prior population studies. The study's authors proposed this may point to PEMF technology's potential as a non-invasive, non-pharmacological approach worth further study — while noting that optimal frequency, strength, and duration parameters are still being explored, and called for larger studies to confirm the mechanism.

This study was funded by Biomobie Regenerative Medicine, the manufacturer of the PEMF technology studied; per the published disclosure, the funder had no role in study conduct, analysis, or manuscript preparation. This research focused on the underlying PEMF technology and protocol, not the current NeuroRester consumer product; the published study used a PEMF device manufactured by Biomobie (Shanghai, China). These statements have not been evaluated by the FDA. NeuroRester is not intended to diagnose, treat, cure, or prevent any disease. Individual results will vary.